I4AA Stock Overview
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Intellipharmaceutics International Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.044 |
| 52 Week High | CA$0.082 |
| 52 Week Low | CA$0.025 |
| Beta | 0.38 |
| 1 Month Change | 0% |
| 3 Month Change | 7.23% |
| 1 Year Change | n/a |
| 3 Year Change | -70.82% |
| 5 Year Change | -75.00% |
| Change since IPO | -99.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| I4AA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0% | 3.2% | 1.7% |
| 1Y | n/a | -28.2% | 2.3% |
Return vs Industry: Insufficient data to determine how I4AA performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how I4AA performed against the German Market.
Price Volatility
| I4AA volatility | |
|---|---|
| I4AA Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: I4AA's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine I4AA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 11 | Isa Odidi | www.intellipharmaceutics.com |
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease.
Intellipharmaceutics International Inc. Fundamentals Summary
| I4AA fundamental statistics | |
|---|---|
| Market cap | €1.81m |
| Earnings (TTM) | -€2.96m |
| Revenue (TTM) | €845.31k |
2.1x
P/S Ratio-0.6x
P/E RatioIs I4AA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I4AA income statement (TTM) | |
|---|---|
| Revenue | US$904.95k |
| Cost of Revenue | US$475.89k |
| Gross Profit | US$429.06k |
| Other Expenses | US$3.60m |
| Earnings | -US$3.17m |
Last Reported Earnings
Aug 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.096 |
| Gross Margin | 47.41% |
| Net Profit Margin | -350.72% |
| Debt/Equity Ratio | -16.9% |
How did I4AA perform over the long term?
See historical performance and comparison